Preliminary Safety of a Bcl-2 Inhibitor, Bgb-11417, in Patients with Relapsed/Refractory Multiple Myeloma Harboring t(11,14): A Non-Randomized, Open-Label, Phase 1b/2 Study
Blood(2022)
关键词
relapsed/refractory multiple myeloma harboring,non-randomized,open-label
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要